Skip to main content
Erschienen in: Archives of Dermatological Research 2/2018

18.01.2018 | Concise Communication

Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity

verfasst von: Goksen Ertugrul, Didem Keles, Gulgun Oktay, Sebnem Aktan

Erschienen in: Archives of Dermatological Research | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Lupus erythematosus is a chronic autoimmune disease characterized by remissions and exacerbations. Accumulated evidence indicated that matrix metalloproteinases (MMPs) are upregulated in inflammatory cells of cutaneous lupus erythematosus (CLE); however, the activity levels of these proteases have remained uncharacterized. To elucidate the significance of MMP-2, MMP-9, and TIMP-1 in CLE pathogenesis, gelatin zymography was used to investigate pro and active levels of MMP-2 and MMP-9 in lesional and perilesional skin biopsies obtained from twenty-two CLE patients. TIMP-1 protein levels were detected by ELISA in the biopsy specimens. The correlation between biochemical parameters and clinical characteristics of the disease was also evaluated. Significantly higher levels of active MMP-2, active MMP-9, proMMP-9, active/proMMP-2, and TIMP-1 were detected in lesional skin samples. Besides, the active/proMMP-9 was elevated in female and smoking patients. Active MMP-9 levels and active/proMMP-9 were also increased in elderly patients. Active MMP-9 levels were lower in patients who had smaller total damage score. Consistently, active/proMMP-9 and active/proMMP-2 were positively correlated with CLASI. Interestingly, in hydroxychloroquine or topical corticosteroid-treated patients, MMP-2/-9 activity levels were found to be higher compared to untreated patients. These findings suggest that increased MMP-2 and MMP-9 activities may contribute to the pathogenesis of CLE and cutaneous disease severity.
Literatur
3.
Zurück zum Zitat Axisa B, Loftus IM, Naylor AR, Goodall S, Jones L, Bell PR, Thompson MM (2002) Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 33:2858–2864CrossRefPubMed Axisa B, Loftus IM, Naylor AR, Goodall S, Jones L, Bell PR, Thompson MM (2002) Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 33:2858–2864CrossRefPubMed
6.
Zurück zum Zitat Djamgoz MBA, Mycielska M, Madeja Z, Fraser SP, Korohoda W (2001) Directional movement of rat prostate cancer cells in direct-current electric field: involvement of voltage-gated Na+ channel activity. J Cell Sci 114:2697–2705PubMed Djamgoz MBA, Mycielska M, Madeja Z, Fraser SP, Korohoda W (2001) Directional movement of rat prostate cancer cells in direct-current electric field: involvement of voltage-gated Na+ channel activity. J Cell Sci 114:2697–2705PubMed
7.
Zurück zum Zitat Faber-Elmann A, Eilat E, Zinger H, Mozes E (2002) A peptide based on an anti-DNA autoantibody downregulates matrix metalloproteinases in murine models of lupus. Clin Immunol 105:223–232CrossRefPubMed Faber-Elmann A, Eilat E, Zinger H, Mozes E (2002) A peptide based on an anti-DNA autoantibody downregulates matrix metalloproteinases in murine models of lupus. Clin Immunol 105:223–232CrossRefPubMed
8.
Zurück zum Zitat Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E (2002) Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 127:393–398CrossRefPubMedPubMedCentral Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E (2002) Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 127:393–398CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90:251–262PubMed Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90:251–262PubMed
14.
Zurück zum Zitat Hardy CJ, Palmer BP, Muir KR, Sutton AJ, Powell RJ (1998) Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study. Ann Rheum Dis 57:451–455CrossRefPubMedPubMedCentral Hardy CJ, Palmer BP, Muir KR, Sutton AJ, Powell RJ (1998) Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study. Ann Rheum Dis 57:451–455CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Heussen C, Dowdle EB (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102:196–202CrossRefPubMed Heussen C, Dowdle EB (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102:196–202CrossRefPubMed
19.
Zurück zum Zitat Matache C, Stefanescu M, Dragomir C, Tanaseanu S, Onu A, Ofiteru A, Szegli G (2003) Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Autoimmun 20:323–331CrossRefPubMed Matache C, Stefanescu M, Dragomir C, Tanaseanu S, Onu A, Ofiteru A, Szegli G (2003) Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Autoimmun 20:323–331CrossRefPubMed
21.
24.
Zurück zum Zitat Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166CrossRefPubMedPubMedCentral Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Robak E, Wierzbowska A, Chmiela M, Kulczycka L, Sysa-Jedrejowska A, Robak T (2006) Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus. Mediat Inflamm 2006:17898. https://doi.org/10.1155/MI/2006/17898 Robak E, Wierzbowska A, Chmiela M, Kulczycka L, Sysa-Jedrejowska A, Robak T (2006) Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus. Mediat Inflamm 2006:17898. https://​doi.​org/​10.​1155/​MI/​2006/​17898
Metadaten
Titel
Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity
verfasst von
Goksen Ertugrul
Didem Keles
Gulgun Oktay
Sebnem Aktan
Publikationsdatum
18.01.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Dermatological Research / Ausgabe 2/2018
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-018-1811-2

Weitere Artikel der Ausgabe 2/2018

Archives of Dermatological Research 2/2018 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.